Early results of an NCI-sponsored Phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer (MBC)

被引：0
|
作者：
Peterson, Lanell [1 ]
Kurland, Brenda [4 ]
Linden, Hannah [2 ]
Link, Jeanne [3 ]
Schubert, Erin [1 ]
Gadi, Vijayakrishna [2 ]
Specht, Jennifer [2 ]
Eary, Janet [3 ]
Shankar, Lalitha [5 ]
Mankoff, David [1 ]
机构：
[1] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Radiol Nucl Med, Seattle, WA 98195 USA
[2] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Med Oncol, Seattle, WA 98195 USA
[3] Univ Washington, Med Ctr, Radiol Nucl Med, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Clin Stat, Seattle, WA 98104 USA
[5] NCI, Canc Imaging Program, Bethesda, MD 20892 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
329
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT
    Yang, Zhongyi
    Sun, Yifei
    Xu, Xiaoping
    Zhang, Yongping
    Zhang, Jianping
    Xue, Jing
    Wang, Mingwei
    Yuan, Huiyu
    Hu, Silong
    Shi, Wei
    Zhu, Beiling
    Zhang, Yingjian
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 421 - 427
  • [32] A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor Rich Postmenopausal Breast Cancer
    Chae, Sun Young
    Kim, Sung-Bae
    Ahn, Sei Hyun
    Kim, Hye Ok
    Yoon, Dok Hyun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Han, Sangwon
    Oh, Seung Jun
    Lee, Sang Ju
    Kim, Hee Jeong
    Son, Byung Ho
    Gong, Gyungyub
    Lee, Hyo Sang
    Moon, Dae Hyuk
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (04) : 563 - 568
  • [33] ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2-metastatic breast cancer: A phase 3 trial
    Bidard, Francois Clement
    Bellesoeur, Audrey
    Hajjaji, Nawale
    Rowinski, Elise
    De Nonneville, Alexandre
    Alexandre, Marie
    Lalire, Paul
    Deleuze, Antoine
    Alix-Panabieres, Catherine
    Turbiez, Isabelle
    Berger, Frederique
    Seban, Romain-David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Uptake of [F-18]-fluoroestradiol (FES) predicts response of recurrent or metastatic breast cancer to hormonal therapy.
    Mankoff, DA
    Peterson, LM
    Stekhova, S
    Schubert, EK
    Link, JM
    Gralow, JR
    Linden, HM
    Livingston, RB
    Krohn, KA
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 126P - 126P
  • [35] Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
    Cheng Liu
    Shihui Hu
    Xiaoping Xu
    Yongping Zhang
    Biyun Wang
    Shaoli Song
    Zhongyi Yang
    Breast Cancer Research, 24
  • [36] Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
    Liu, Cheng
    Hu, Shihui
    Xu, Xiaoping
    Zhang, Yongping
    Wang, Biyun
    Song, Shaoli
    Yang, Zhongyi
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [37] [18F]-fluoroestradiol (FES) Brain PET in the Evaluation of Patients with Estrogen Receptor Positive Breast Cancer Brain Metastases
    Sharbatdaran, Arman
    Osborne, Joseph
    Agee, Matthew
    Magge, Rajiv
    Jonathan, Knisely
    Schwartz, Theodore
    Pannullo, Susan
    Brandmaier, Andrew
    Andreopoulou, Eleni
    Ramakrishna, Rohan
    Ivanidze, Jana
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [38] Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC).
    Moulder, SL
    Munster, P
    Minton, S
    Diaz, N
    Horton, J
    Lima, CR
    Hutson, L
    Sullivan, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [39] A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
    Peterson, Lanell M.
    Kurland, Brenda F.
    Schubert, Erin K.
    Link, Jeanne M.
    Gadi, V. K.
    Specht, Jennifer M.
    Eary, Janet F.
    Porter, Peggy
    Shankar, Lalitha K.
    Mankoff, David A.
    Linden, Hannah M.
    MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (03) : 431 - 440
  • [40] A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
    Lanell M. Peterson
    Brenda F. Kurland
    Erin K. Schubert
    Jeanne M. Link
    V.K. Gadi
    Jennifer M. Specht
    Janet F. Eary
    Peggy Porter
    Lalitha K. Shankar
    David A. Mankoff
    Hannah M. Linden
    Molecular Imaging and Biology, 2014, 16 : 431 - 440
12345